NervGen Pharma Corp. (NGEN.V)

CAD 2.95

(0.0%)

Operating Expenses Summary of NervGen Pharma Corp.

NervGen Pharma Corp.'s latest annual operating expenses in 2023 was 17.77 Million CAD , down -22.79% from previous year.
NervGen Pharma Corp.'s latest quarterly operating expenses in 2024 Q2 was 6 Million CAD , up 19.71% from previous quarter.
NervGen Pharma Corp. reported a annual operating expenses of 23.02 Million CAD in annual operating expenses 2022, up 79.73% from previous year.
NervGen Pharma Corp. reported a annual operating expenses of 12.81 Million CAD in annual operating expenses 2021, up 14.43% from previous year.
NervGen Pharma Corp. reported a quarterly operating expenses of 6 Million CAD for 2024 Q2, up 19.71% from previous quarter.
NervGen Pharma Corp. reported a quarterly operating expenses of 4.76 Million CAD for 2023 Q2, up 1.12% from previous quarter.

Annual Operating Expenses Chart of NervGen Pharma Corp. (2023 - 2017)

Historical Annual Operating Expenses of NervGen Pharma Corp. (2023 - 2017)

Year	Operating Expenses	Operating Expenses Growth
2023	17.77 Million CAD	-22.79%
2022	23.02 Million CAD	79.73%
2021	12.81 Million CAD	14.43%
2020	11.19 Million CAD	13.5%
2019	9.86 Million CAD	626.14%
2018	1.35 Million CAD	11399.9%
2017	11.81 Thousand CAD	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q1	5 Million CAD	3.39%
2024 Q2	6 Million CAD	19.71%
2023 Q2	4.76 Million CAD	1.12%
2023 Q1	4.71 Million CAD	-30.47%
2023 FY	17.63 Million CAD	-23.42%
2023 Q4	4.83 Million CAD	41.58%
2023 Q3	3.41 Million CAD	-28.38%
2022 Q1	5 Million CAD	20.69%
2022 FY	23.02 Million CAD	79.73%
2022 Q4	6.78 Million CAD	37.78%
2022 Q3	4.92 Million CAD	-22.01%
2022 Q2	6.31 Million CAD	26.15%
2021 FY	12.81 Million CAD	14.43%
2021 Q4	4.14 Million CAD	13.08%
2021 Q3	3.66 Million CAD	32.51%
2021 Q2	2.76 Million CAD	24.09%
2021 Q1	2.23 Million CAD	-49.47%
2020 Q3	2.05 Million CAD	-16.54%
2020 FY	11.19 Million CAD	13.5%
2020 Q1	2.27 Million CAD	-21.77%
2020 Q2	2.45 Million CAD	8.12%
2020 Q4	4.41 Million CAD	115.17%
2019 Q4	2.9 Million CAD	22.84%
2019 Q2	1.56 Million CAD	-48.09%
2019 Q1	3.02 Million CAD	293.71%
2019 Q3	2.36 Million CAD	50.72%
2019 FY	9.86 Million CAD	626.14%
2018 Q2	64.35 Thousand CAD	505.7%
2018 Q3	515.54 Thousand CAD	701.15%
2018 Q4	767.96 Thousand CAD	48.96%
2018 FY	1.35 Million CAD	11399.9%
2018 Q1	10.62 Thousand CAD	0.0%
2017 FY	11.81 Thousand CAD	0.0%

Peer Operating Expenses Comparison of NervGen Pharma Corp.

Name	Operating Expenses	Operating Expenses Difference
Arch Biopartners Inc.	3.22 Million CAD	-451.016%
Covalon Technologies Ltd.	14.36 Million CAD	-23.777%
Hemostemix Inc.	2.15 Million CAD	-724.238%
Universal Ibogaine Inc.	5.81 Million CAD	-205.597%
Kane Biotech Inc.	3.46 Million CAD	-412.762%
MedMira Inc.	1.5 Million CAD	-1077.728%
Marvel Biosciences Corp.	2.31 Million CAD	-666.59%
XORTX Therapeutics Inc.	6.38 Million CAD	-178.55%